![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x675.jpg)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![NCA - Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) - Decision Memo NCA - Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) - Decision Memo](http://www.cms.gov/medicare/coverage/determinationprocess/other-content-types/id274image011png.png)
NCA - Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) - Decision Memo
![Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter - Brachytherapy Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter - Brachytherapy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/877a1a88-7263-4483-a339-117d79023fdf/gr1.jpg)
Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter - Brachytherapy
Preliminary study for dose evaluation depending on dose range with optically stimulated luminescence dosimeter considering individual dosimeter sensitivity | PLOS ONE
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study | The BMJ Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study | The BMJ](https://www.bmj.com/content/bmj/372/bmj.n37/F1.medium.jpg)